Clinical trial
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed…
NCT00039871 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00039871 |
|---|---|
| Title | PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) |
| Official title | PEG-Intron Plus REBETOL for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Alpha Interferon Treatment in Combination With Ribavirin) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis, Hepatitis C, Chronic, Fibrosis, Liver Cirrhosis |
| Intervention type | Biological, Drug |
| Interventions | PegIntron (peginterferon alfa-2b, SCH 54031), REBETOL (ribavirin, SCH 18908) |
| Enrollment | 2,333 |
| Start date | May 1, 2002 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jun 14, 2002 |
| Last update posted | Apr 4, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: